A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...

A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

News, features, and commentary about cancer-related issues ...

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

New research suggests childhood cancer survivors may experience accelerated biological aging from treatments, potentially ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Crucially, in their analysis, the researchers excluded the use of PPIs in one year before stomach cancer diagnoses. That's because stomach cancer symptoms can often show up as pain, reflux and ...